Hammond Billy R, Fletcher Laura M, Roos Franz, Wittwer Jonas, Schalch Wolfgang
Vision Sciences and Human Biofactors Laboratories, Department of Psychology, University of Georgia, Athens, Georgia, United States.
DSM Nutritional Products Ltd., Wurmisweg, Kaiseraugst, Switzerland.
Invest Ophthalmol Vis Sci. 2014 Dec 2;55(12):8583-9. doi: 10.1167/iovs.14-15573.
Past studies have shown that higher macular pigment optical density (MPOD) and lutein (L) and zeaxanthin (Z) supplementation are related to improvements in glare disability, photostress recovery, and chromatic contrast. This study assessed those links using a randomized, double-blind, placebo-controlled design.
The visual effects of 1 year of supplementing L (10 mg/d) and Z (2 mg/d) were investigated. One hundred fifteen young, healthy subjects were recruited and randomized into the study (58 received placebo, 57 L+Z). Several dependent measures were collected at baseline and then once every 3 months: serum L and Z measured by HPLC chromatography; MPOD measured using customized heterochromatic flicker photometry; photostress recovery assessed by measuring the time needed to recover visual acquisition of a grating target after 30 seconds of an intense xenon white flash exposure; glare disability evaluated as the energy in a surrounding annulus necessary to veil a central grating target; and chromatic contrast assessed by measuring thresholds for a yellow grating target superposed on a 460-nm background.
Macular pigment optical density increased significantly versus placebo at all eccentricities (10, 30, 60, and 105 minutes from the center of the macula). Serum L and Z also increased significantly by the first follow-up visit (at 3 months), and remained elevated throughout the intervention period of 1 year. Chromatic contrast and photostress recovery time improved significantly versus placebo. Glare disability was correlated with macular pigment density throughout the study period but did not increase significantly in the treated group.
Daily supplementation with L+Z resulted in significant increase in serum levels and MPOD and improvements in chromatic contrast and recovery from photostress. These results are consistent with past studies showing that increasing MPOD leads to improved visual performance. (ClinicalTrials.gov number, NCT00909090.).
既往研究表明,较高的黄斑色素光密度(MPOD)以及叶黄素(L)和玉米黄质(Z)补充剂与眩光残疾、光应激恢复和色对比度的改善有关。本研究采用随机、双盲、安慰剂对照设计评估这些关联。
研究了补充L(10毫克/天)和Z(2毫克/天)1年的视觉效果。招募了115名年轻健康受试者并随机分组进入研究(58人接受安慰剂,57人接受L+Z)。在基线时以及之后每3个月收集若干相关测量指标:通过高效液相色谱法测定血清L和Z;使用定制的异色闪烁光度法测量MPOD;通过测量在强烈氙白闪光暴露30秒后恢复对光栅目标视觉识别所需的时间来评估光应激恢复;将眩光残疾评估为遮蔽中央光栅目标所需的周围环形区域的能量;通过测量叠加在460纳米背景上的黄色光栅目标的阈值来评估色对比度。
与安慰剂相比,在所有偏心度(距黄斑中心10、30、60和105分钟处)下,黄斑色素光密度均显著增加。血清L和Z在首次随访(3个月时)也显著增加,并在1年的干预期内一直保持升高。与安慰剂相比,色对比度和光应激恢复时间显著改善。在整个研究期间,眩光残疾与黄斑色素密度相关,但治疗组中未显著增加。
每日补充L+Z导致血清水平和MPOD显著增加,色对比度改善以及光应激恢复。这些结果与既往研究一致,表明增加MPOD可改善视觉性能。(临床试验注册号,NCT00909090。)